Sysmex ADR Net Long-Term Debt 2016-2024 | SSMXY
Sysmex ADR annual/quarterly net long-term debt history and growth rate from 2016 to 2024. Net long-term debt can be defined as the net amount of long term debt issued and repaid. This field is either calculated as the sum of the long term debt fields or used if a company does not report debt issued and repaid separately
- Sysmex ADR net long-term debt for the quarter ending December 31, 2024 was $0.014B, a 0% increase year-over-year.
- Sysmex ADR net long-term debt for the twelve months ending December 31, 2024 was $-0.001B, a 0% increase year-over-year.
- Sysmex ADR annual net long-term debt for 2024 was $0.192B, a 0% decline from 2023.
- Sysmex ADR annual net long-term debt for 2023 was $0B, a 0% decline from 2022.
- Sysmex ADR annual net long-term debt for 2022 was $0B, a 0% decline from 2021.
| Sysmex ADR Annual Net Long-Term Debt (Millions of US $) |
|
|---|---|
| 2024 | $192 |
| 2023 | $N/A |
| 2022 | $N/A |
| 2021 | $N/A |
| 2020 | $N/A |
| 2019 | $N/A |
| 2018 | $N/A |
| 2017 | $N/A |
| 2016 | $0 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED INSTRUMENTS | $11.453B | $3.197B |
| Sysmex Corporation is engaged in the development, manufacture, import, export and sale of clinical laboratory instruments, reagents and software used in -vitro diagnostics. It also provides clinical laboratory testing of blood, urine and other specimens. The company's product includes instruments and reagents diagnostics for hemostasis, immunochemistry, clinical chemistry, urinalysis and point-of-care testing. Its operating segment consists of Japan, Americas, EMEA, China and Asia Pacific. Sysmex Corporation is headquartered in Kobe, Japan. | |||